Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
In the AlphaLISA® SureFire® Ultra™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.
AlphaLISA® SureFire® Ultra™ kits are compatible with:
Alpha SureFire® kits can be used for:
|Assay Target Class||Phosphoprotein|
|Product Brand Name||AlphaLISA SureFire Ultra|
|Quantity in a Package Amount||500.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System, Cardiovascular, Metabolic|
|Unit Size||500 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
Evaluating pharmaceutical compound efficacy and safety in regulating cell behavior can involve the study of multiple signal transduction pathways and measuring more than one cellular target can provide greater confidence of positive compound hits on the cellular target of interest. Protein phosphorylation has been identified as a useful readout of cellular activation or inhibition, and these pathways are commonly targeted for therapeutic modulation of disease.
Numerous assay technologies are available to look at protein phosphorylation for drug development, including the AlphaLISA SureFire Ultra which provides a highly sensitive, fully homogenous option for the analysis of signaling pathways. In this application note, we describe the implementation of multiplexing with the AlphaLISA SureFire Ultra Multiplex assay, the only multiplexing platform that is truly homogenous and high throughput.
In this application note, we demonstrate an efficient cell-based workflow for the assessment of EGF treatment effects in a cellular model of human skin cancer.
Treatment effects on several intracellular signaling pathways were examined using PerkinElmer’s homogeneous, no-wash AlphaLISA® SureFire® Ultra assays. To determine concurrent time-dependent effects of different EGF concentrations on cellular health and proliferation, ATP concentrations were assessed with ATPlite™ 1step luminescence assay and cultures were fluorescently labeled, imaged and analyzed using the Operetta CLS™ high-content analysis system.